ACSI has also owned and operated market leading consumer brands such as SABCO, Britex Carpet care, Crystal Clear, Rug Doctor and Dynamo house, and other consumer brands.
Mr. Anastasiou has an excellent track record in corporate restructure and financial management, and investment, including the acquisition and turnaround of a number of companies in the last 15 years. Most recently he has managed the restructure, and consolidated the future of the iconic Australia brand SABCO, established in South Australia in 1894.
Mr Anastasiou through Investment fund Grandlodge is a contrarian investor who during the height of the GFC bought over 10% interests in listed Australian Companies Mcphersons Ltd and Norfolk Limited, and added significantly to the groups land holdings.
Mr. Anastasiou has a long history of philanthropic activities which includes the patron of Identity Theatre – a company designed to assist men with issues of depression self esteem and identity. He was also a board member and supporter of the Indigenous Eye Health Unit at Melbourne University that has significantly reduced Trachoma in the Northern Australian Aboriginal communities. Mr Anastasiou is also a significant supporter of the John Fawcett foundation in Bali whose work includes restoring sight to children and adults with Cataracts.
He is happily married with three children, and his other interests include breeding slow horses and fast cattle, a trend he is currently trying to reverse, golf and soccer. He has a psychology degree from Latrobe University, and sits on several boards. Mr Anastasiou was a founding investor and previous Board Member of the successful Melbourne Victory Football Club.
Mr Anastasiou has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry.
His breadth of experience incorporates medical diagnostics, pharmaceuticals,
hospital, dental and OTC products, with companies including the international
pharmaceutical company Bristol Myer Squibb.
While employed as a management consultant with KPMG Peat Marwick, Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector.
He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management.
Board appointments include, Non-executive Director of the Australian Biotechnology Company IMMURON LTD. ( ASX:IMC)
Mr Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.